Christina Zielinski

Prof. Dr. Christina Zielinski

Infection Immunology, Leibniz Institute for Natural Product Research and Infection Biology, Jena, Germany

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2012 in Nature
Verified
Journal Article
Closed access
Christina ZielinskiChristina Zielinski
Christina Zielinski
FMFederico Mele
Federico Mele
DADominik Aschenbrenner
Dominik Aschenbrenner
DJDavid Jarrossay
David Jarrossay
FRFrancesca Ronchi
Francesca Ronchi
FSFederica Sallusto
Federica Sallusto

18 June 2014 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
RNRebecca Noster
Rebecca Noster
RRRené Riedel
René Riedel
MMMir-Farzin Mashreghi
Mir-Farzin Mashreghi
HRHelena Radbruch
Helena Radbruch
LHLutz Harms
Lutz Harms
Christina ZielinskiChristina Zielinski
Christina Zielinski
GM-CSF–producing T helper cells in humans follow a distinct regulation program as compared to T H 17 cells and are associated with multiple sclerosis.

5 September 2012 in European Journal of Immunology
Verified
Journal Article
Closed access
PDF file
FSFederica Sallusto
Federica Sallusto
Christina ZielinskiChristina Zielinski
Christina Zielinski
ALAntonio Lanzavecchia
Antonio Lanzavecchia

12 September 2016 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
TTTakanobu Tagawa
Takanobu Tagawa
MAManuel Albanese
Manuel Albanese
MBMickaël Bouvet
Mickaël Bouvet
AMAndreas Moosmann
Andreas Moosmann
JMJosef Mautner
Josef Mautner
WHWolfgang Hammerschmidt
Wolfgang Hammerschmidt
Epstein-Barr virus (EBV) is a tumor virus that establishes lifelong infection in most of humanity, despite eliciting strong and stable virus-specific immune responses. EBV encodes at least 44 miRNAs, most of them with unknown function. Here, we show that multiple EBV miRNAs modulate immune recognition of recently infected primary B cells, EBV's natural target cells. EBV miRNAs collectively and specifically suppress release of proinflammatory cytokines such as IL-12, repress differentiation of naive CD4+ T cells to Th1 cells, interfere with peptide processing and presentation on HLA class II, and thus reduce activation of cytotoxic EBV-specific CD4+ effector T cells and killing of infected B cells. Our findings identify a previously unknown viral strategy of immune evasion. By rapidly expressing multiple miRNAs, which are themselves nonimmunogenic, EBV counteracts recognition by CD4+ T cells and establishes a program of reduced immunogenicity in recently infected B cells, allowing the virus to express viral proteins required for establishment of life-long infection.

23 February 2011 in Immunological Reviews
Verified
Journal Article
Closed access
PDF file
Christina ZielinskiChristina Zielinski
Christina Zielinski
DCDavide Corti
Davide Corti
FMFederico Mele
Federico Mele
DPDora Pinto
Dora Pinto
ALAntonio Lanzavecchia
Antonio Lanzavecchia
FSFederica Sallusto
Federica Sallusto

20 February 2019 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
JMJulia Matthias
Julia Matthias
JMJulia Maul
Julia Maul
RNRebecca Noster
Rebecca Noster
HMHanna Meinl
Hanna Meinl
YCYing-Yin Chao
Ying-Yin Chao
Christina ZielinskiChristina Zielinski
Christina Zielinski
Sodium chloride induces and amplifies human T H 2 cell responses, potentially shaping the atopic skin microenvironment.